Nevro Names Kevin Thornal as CEO

Nevro, a company developing solutions to treat chronic pain, has appointed Kevin Thornal as its new CEO, effective April 24. Thornal will also be appointed to the company’ board of directors.
 
Thornal succeeds D. Keith Grossman, who is retiring as CEO and president effective April 14. Grossman will be named to serve as executive chairman.
 
“On behalf of the Board and our entire company, I am excited to welcome Kevin to the Nevro team,” Grossman told the press. “Throughout his career, Kevin has established an excellent track record of leading medical technology businesses that deliver strong growth and commercial excellence. Kevin is an impressive rising leader in our industry and is an ideal fit in every way with where Nevro is today and where we believe it can go in the future. It’s been a great privilege to lead this company over the past four years and extremely rewarding to work alongside the talented and dedicated individuals who are committed to Nevro’s vision, mission and values.  I look forward to a smooth transition and to working to support Kevin and his team as Executive Chairman.”
 
Thornal (49) has 20 years of senior management experience. He spent nine years at Hologic, where he was most recently group president of Global Diagnostic Solutions since April 2022. He joined in 2014 as VP, Customer Experience, Field Service and Clinical Applications for the Breast and Skeletal Health division. He transitioned to VP, Breast and Skeletal Health for the Europe, Middle East and Africa region in early 2016, and was promoted to president of Medical Aesthetics in July 2017. In July 2019 he was promoted to president of Diagnostic Solutions.
 
Before Hologic, Thornal had several roles at Stryker from 2004 to 2014 in sales, marketing, and business development.
 
“I am delighted to join Nevro at this exciting time and look forward to furthering its mission of delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment,” said Thornal. “Keith and the Nevro team have built a powerful platform for Nevro’s future. I am proud to join this talented team and am committed to further advancing Nevro’s vision and strategy and to delivering attractive returns to our shareholders.”